Semaglutide and Tirzepatide are both glucagon-like peptide-1 (GLP-1) receptor agonists widely used in diabetes treatment. Semaglutide, available as injections (e.g., Ozempic) or oral tablets (Rybelsus), lowers blood sugar by enhancing insulin secretion and reducing appetite. Tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, shows stronger glycemic control and weight loss effects in clinical trials. Both drugs help manage type 2 diabetes, with Tirzepatide gaining attention for potential obesity treatment due to significant weight reduction outcomes.
